Aura Biosciences Inc (AURA)
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors. The company’s proprietary platform uses virus-like particles that are either conjugated with drugs or loaded with nucleic acids, with the goal of targeting a range of solid tumor indications. Its lead candidate, bel-sar, is being studied in late-stage development for primary choroidal melanoma and other ocular oncology uses, and in earlier-stage development for bladder cancer. Aura Biosciences was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AURA
|
$6.70
|
4.0% Upside
|
Fair
|
$16.60
|
157.8% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
2.1x
|
667.9 M
|
360.6 M
|
2.4%
|
76.8%
|
10.0
|
78.9%
|
